RxSight
RxSight's revenue fell 3.9% to $134 million in fiscal 2025. Its operating margin was −35.8%, down from −26.3% a year earlier. Free cash flow was −$19 million. The diluted share count rose 5.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
RxSight lost money in fiscal 2025: a net loss of $39 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 159 | 106 | 127 | 237 | 228 |
| Debt incl. finance leases | 40 | 40 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −120 | −65 | −127 | −237 | −228 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.5x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −14.3x | −12.8x | −15.1x | −1,755.1x | −2,536.4x |
| Current ratio | 15.9x | 7.8x | 8.1x | 11.4x | 10.9x |
| Quick ratio | 15.2x | 7.0x | 7.2x | 10.5x | 9.8x |
Cash flow
Projections
Project RxSight's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought RxSight shares on the open market, and 3 insiders sold $103,745.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Mark WilterdingChief Financial Officer | Sold | 7,765 | $6.96 | $54,044 | Form 4 |
| Sep 2, 2026 | Ronald M MD KurtzChief Medical Officer | Sold | 5,100 | $6.96 | $35,496 | Form 4 |
| Sep 2, 2026 | Eric WeinbergSee remarks | Sold | 2,041 | $6.96 | $14,205 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 3 of 9 |
| Rule of 40 | 29.7% | 41.1% | −18.3% |
| Altman Z'' | 0.43 | 6.29 | 5.56 |
| Accruals ratio | −4.2% | −4.2% | −7.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 6 of 9 | 5 of 9 | 3 of 9 |
Compare
Put RxSight side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| RxSight | FY25 | −3.9% | −35.8% | −14.4% | −82.9% | — | 3 | |
| Alpha Pro Tech | FY25 | 2.2% | 6.5% | 2.9% | — | — | — | Compare |
| Organogenesis | FY25 | 17.0% | 7.9% | −4.3% | — | — | — | Compare |
| ImmuCell | FY25 | 4.3% | 6.0% | 4.4% | — | 1.2x | — | Compare |
| Neogen | FY26 | −2.7% | −2.5% | 3.7% | −0.6% | 6.4x | 5 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 15 | 23 | 49 | 89 | 140 | 134 |
| Revenue growth | — | 53.9% | 116.9% | 81.8% | 57.1% | −3.9% |
| Gross profit | 2 | 4 | 21 | 54 | 99 | 103 |
| Research and development | 22 | 24 | 26 | 29 | 34 | 38 |
| Operating income | −35 | −53 | −63 | −50 | −37 | −48 |
| Net income | 28 | −49 | −67 | −49 | −28 | −39 |
| Diluted EPS (US$) | 0.15 | −3.57 | −2.41 | −1.41 | −0.71 | −0.95 |
| Diluted shares (millions) | 6 | 14 | 28 | 34 | 39 | 41 |
| Cash flow | ||||||
| Cash from operations | −35 | −45 | −59 | −42 | −17 | −16 |
| Capital expenditure | 2 | 2 | 2 | 5 | 5 | 4 |
| Free cash flow | −38 | −47 | −61 | −46 | −22 | −19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 8 | 11 | 16 | 25 | 32 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 69 | 159 | 106 | 127 | 237 | 228 |
| Debt incl. finance leases | 24 | 40 | 40 | 0 | 0 | 0 |
| Total assets | 101 | 193 | 150 | 182 | 319 | 312 |
| Total liabilities | 45 | 54 | 60 | 22 | 37 | 36 |
| Shareholders' equity | −431 | 138 | 90 | 160 | 281 | 276 |
| Margins and ratios | ||||||
| Gross margin | 11.6% | 20.0% | 43.5% | 60.4% | 70.7% | 76.6% |
| Operating margin | −241.3% | −233.6% | −129.2% | −56.2% | −26.3% | −35.8% |
| Net margin | 187.9% | −215.5% | −136.2% | −54.6% | −19.6% | −29.0% |
| Free cash flow margin | −257.1% | −206.5% | −125.0% | −52.1% | −16.0% | −14.4% |
| Rule of 40 (growth + FCF margin) | — | −152.6% | −8.1% | 29.7% | 41.1% | −18.3% |
| Return on capital | — | — | −231.6% | −136.9% | −75.2% | −82.9% |
| Return on equity | — | — | −58.5% | −38.9% | −12.4% | −14.0% |
| Return on assets | — | −33.2% | −38.9% | −29.2% | −11.0% | −12.4% |
| Net debt to EBITDA | — | — | — | — | — | — |